Precigen (PGEN) Asset Writedowns and Impairment (2014 - 2023)
Precigen (PGEN) posted quarterly Asset Writedowns and Impairment of $445000.0 for Q4 2023, down 30.25% quarter-over-quarter from $638000.0 in Q2 2022.
Powered by 
Analysis
Precigen (PGEN) Asset Writedowns and Impairment (2014 - 2023) Analysis & Trends
Precigen (PGEN) has reported Asset Writedowns and Impairment for 10 consecutive years, with $445000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $445000.0; the TTM figure through Jun 2025 stood at $445000.0 (changed N/A YoY), while the FY2024 annual figure was $32.9 million, up 7296.63% from the prior year.
- Asset Writedowns and Impairment fell to $445000.0 in Q4 2023 per PGEN's latest filing, from $638000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $2.8 million in Q4 2019 and bottomed at -$676000.0 in Q4 2021.
- Historically, Asset Writedowns and Impairment has averaged $527916.7 across 5 years, with a median of $446500.0 in 2019.
- Annual changes were most pronounced in 2019 — Asset Writedowns and Impairment jumped 1435.16% — and 2021, when it sank 582.86%.
- Precigen's Asset Writedowns and Impairment stood at $2.8 million in 2019, then plunged by 94.99% to $140000.0 in 2020, then tumbled by 582.86% to -$676000.0 in 2021, then soared by 194.38% to $638000.0 in 2022, then slumped by 30.25% to $445000.0 in 2023.
- Business Quant data shows PGEN's Asset Writedowns and Impairment at $445000.0 in Q4 2023, $638000.0 in Q2 2022, and $334000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 445,000.00 |
| Jun 30, 2022 | 638,000.00 |
| Mar 31, 2022 | 334,000.00 |
| Dec 31, 2021 | 49,000.00 |
| Jun 30, 2021 | 543,000.00 |
| Mar 31, 2021 | 162,000.00 |
| Sep 30, 2020 | 920,000.00 |
| Jun 30, 2020 | 11.88 Mn |
| Mar 31, 2020 | 523,000.00 |
| Dec 31, 2019 | 31.84 Mn |
| Sep 30, 2019 | 626,000.00 |
| Mar 31, 2019 | 64,000.00 |
| Dec 31, 2018 | 58.91 Mn |
| Jun 30, 2018 | 571,000.00 |
| Mar 31, 2018 | 218,000.00 |
| Dec 31, 2017 | 15.68 Mn |
| Sep 30, 2017 | 511,000.00 |
| Jun 30, 2017 | 573,000.00 |
| Mar 31, 2017 | 9,000.00 |
| Dec 31, 2016 | 354,000.00 |